Free Trial

Sabra Health Care REIT (SBRA) Stock Forecast & Price Target

Sabra Health Care REIT logo
$18.31 -0.08 (-0.44%)
(As of 11:50 AM ET)

Sabra Health Care REIT - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
6

Based on 7 Wall Street analysts who have issued ratings for Sabra Health Care REIT in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for SBRA.

Consensus Price Target

$18.71
2.21% Upside
According to the 7 analysts' twelve-month price targets for Sabra Health Care REIT, the average price target is $18.71. The highest price target for SBRA is $21.00, while the lowest price target for SBRA is $17.00. The average price target represents a forecasted upside of 2.21% from the current price of $18.31.
Get the Latest News and Ratings for SBRA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sabra Health Care REIT and its competitors.

Sign Up

SBRA Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.71$18.38$16.40$14.59
Forecasted Upside2.21% Upside-1.58% Downside-1.38% Downside1.19% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold

SBRA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SBRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sabra Health Care REIT Stock vs. The Competition

TypeSabra Health Care REITFinance CompaniesS&P 500
Consensus Rating Score
2.86
2.49
2.50
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside2.66% Upside12.88% Upside9.87% Upside
News Sentiment Rating
Positive News

See Recent SBRA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/11/2024Scotiabank
5 of 5 stars
 Boost TargetSector Perform ➝ Sector Perform$17.00 ➝ $18.00+0.11%
10/1/2024Wells Fargo & Company
3 of 5 stars
J. Feldman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00+7.47%
9/13/2024Citigroup
3 of 5 stars
N. Joseph
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$17.00 ➝ $20.00+8.99%
9/4/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$16.00 ➝ $18.00+4.23%
2/29/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$17.00+22.92%
1/30/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$21.00+55.79%
1/3/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$15.00 ➝ $17.00+19.63%
11/7/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$14.00 ➝ $16.00+14.94%
10/17/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$16.00+9.89%
10/10/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$14.00 ➝ $16.00+14.20%
9/20/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$11.00 ➝ $15.00+12.28%
7/27/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$13.00-0.99%
4/25/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$15.00 ➝ $13.00+18.18%
4/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$13.00+10.64%
12/13/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:13 PM ET.


SBRA Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Sabra Health Care REIT is $18.71, with a high forecast of $21.00 and a low forecast of $17.00.

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sabra Health Care REIT in the last twelve months. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SBRA shares.

According to analysts, Sabra Health Care REIT's stock has a predicted upside of 2.21% based on their 12-month stock forecasts.

Over the previous 90 days, Sabra Health Care REIT's stock had 2 upgrades by analysts.

Sabra Health Care REIT has been rated by research analysts at Citigroup, Scotiabank, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like Sabra Health Care REIT more than other "finance" companies. The consensus rating for Sabra Health Care REIT is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how SBRA compares to other companies.


This page (NASDAQ:SBRA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners